SA and Italy starting to 
treat patients in 2023. The decrease in REBIT in the period reflects the 
customer-related delays in backlog conversion 
of some ProteusPLUS projects in China and 
project mix, including older lower margin 
projects. In 
addition, targeted 
investment 
(EUR 000) 
FY 2023 
FY 2022 
Variance 
Variance % 
Equipment Proton Therapy 
113 449 
110 162 
3 287 
3.0% 
Services Proton Therapy 
115 616 
108 599 
7 017 
6.5% 
Net sales 
229 065 
218 761 
10 304 
4.7% 
REBIT2 
-23 40